Miner Company
An 8-Hour AI Result Is Testing Pharma's $10 Billion Royalty Market
The drug royalty business thrives on a bet that an approved biologic will keep printing money along a predictable schedule. Patent expires here, biosimilar enters there, revenue declines at roughly this rate.
The drug royalty business thrives on a bet that an approved biologic will keep printing money along a predictable schedule. Patent expires here, biosimilar enters there, revenue declines at roughly this rate.